

Crimean-Congo Hemorrhagic Fever Virus for Clinicians— Diagnosis, Clinical Management, and Therapeutics

Maria G. Frank, Gretchen Weaver, Vanessa Raabe;¹ State of the Clinical Science Working Group of the National Emerging Pathogens Training and Education Center's Special Pathogens Research Network²



In support of improving patient care, this activity has been planned and implemented by Medscape, LLC and Emerging Infectious Diseases. Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Medscape, LLC designates this Journal-based CME activity for a maximum of 1.00 **AMA PRA Category 1 Credit(s)**[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

All other clinicians completing this activity will be issued a certificate of participation. To participate in this journal CME activity: (1) review the learning objectives and author disclosures; (2) study the education content; (3) take the post-test with a 75% minimum passing score and complete the evaluation at https://www.medscape.org/qna/processor/71556?showStandAlone=true&src=prt_jcme_eid_mscpedu; and (4) view/print certificate. For CME questions, see page 1066.

NOTE: It is Medscape's policy to avoid the use of brand names in accredited activities. However, in an effort to be as clear as possible, the use of brand names should not be viewed as a promotion of any brand or as an endorsement by Medscape of specific products.

Release date: April 18, 2024; Expiration date: April 18, 2025

Learning Objectives

Upon completion of this activity, participants will be able to:

1. Evaluate diagnostic tools in cases of suspected Crimean-Congo hemorrhagic fever (CCHF)
2. Analyze characteristics of laboratory tests for CCHF virus
3. Assess the current statuses of vaccinations to protect against CCHF
4. Evaluate treatment options for CCHF

CME Editor

Amy J. Guinn, BA, MA, Technical Writer/Editor, Emerging Infectious Diseases. *Disclosure: Amy J. Guinn, BA, MA, has no relevant financial relationships.*

CME Author

Charles P. Vega, MD, Health Sciences Clinical Professor of Family Medicine, University of California, Irvine School of Medicine, Irvine, California. *Disclosure: Charles P. Vega, MD, has the following relevant financial relationships: served as a consultant or advisor for Boehringer Ingelheim; GlaxoSmithKline.*

Authors

Maria G. Frank, MD; Gretchen Weaver, MPH; Vanessa Raabe, MD, MSc.

Author affiliations: Denver Health and Hospital Authority, Denver, Colorado, USA (M.G. Frank); University of Colorado School of Medicine, Denver (M.G. Frank); University of Massachusetts Chan Medical School, Worcester, Massachusetts, USA (G. Weaver); New York University Grossman School of Medicine, New York, New York, USA (V. Raabe)

DOI: <https://doi.org/10.3201/eid3005.231648>

¹Current affiliation: Pfizer Inc., New York, New York, USA. These materials reflect only the personal views of the author and may not reflect the views of her employer.

²Members of this group are listed at the end of this article.

Crimean-Congo hemorrhagic fever virus (CCHFV) is the most geographically widespread tickborne viral infection worldwide and has a fatality rate of up to 62%. Despite its widespread range and high fatality rate, no vaccines or treatments are currently approved by regulatory agencies in the United States or Europe. Supportive treatment remains the standard of care, but the use of antiviral medications developed for other viral infections have been considered. We reviewed published literature to summarize the main aspects of CCHFV infection in humans. We provide an overview of diagnostic testing and management and medical countermeasures, including investigational vaccines and limited therapeutics. CCHFV continues to pose a public health threat because of its wide geographic distribution, potential to spread to new regions, propensity for genetic variability, potential for severe and fatal illness, and limited medical countermeasures for prophylaxis and treatment. Clinicians should become familiar with available diagnostic and management tools for CCHFV infections in humans.

Approximately 10,000–15,000 cases of human Crimean-Congo hemorrhagic fever (CCHF) occur annually worldwide (1–3). However, more definitive case numbers are difficult to ascertain because up to 88% of infections are thought to be subclinical (1–3), unrecognized, or occurring in locations with limited disease surveillance or laboratory testing capability (4,5). CCHF virus (CCHFV) causes a spectrum of human clinical manifestations, ranging from asymptomatic infection to a severe hemorrhagic fever marked by shock and multiorgan failure (Figure). During CCHF outbreaks, the case-fatality rate ranges from 5% to 30% (1), and some published case series have reported fatality rates up to 62% (6). Disease caused by CCHFV infection is limited to humans, but asymptomatic transient viremia lasting up to 15 days has been documented in livestock and wild animals (7). Severe or fatal disease correlates with an exuberant proinflammatory immune response leading to vascular dysfunction, disseminated intravascular coagulation, multiorgan failure, and shock (8). Although the detection of IgM (usually present as early as day 4–5 of illness) and IgG (usually detectable after days 7–9 of illness) correlates with declining viremia, fatal cases of CCHF often mount no or very late immune responses (9). However, the antibody response to CCHFV does not correlate with disease outcome or protection from vaccines. That feature of CCHF, combined with a paucity of available animal models (10), makes vaccine and treatment research challenging. The US Food and Drug Administration (FDA) has

not approved any vaccines or treatments for CCHF. Ribavirin is commonly used for treatment but clinical evidence regarding its benefit is mixed. Another antiviral medication, favipiravir, shows promise in animal models but has rarely been used in human CCHF management. Vaccine candidates are mostly in preclinical development, and few have advanced to human clinical trials to date.

This third article in a 3-part series summarizing the main aspects of CCHF is intended to provide clinicians with an overview of diagnostic testing, management, and medical countermeasures for CCHF. The first article focuses on the virology, pathogenesis, and pathology of CCHF (11) and the second on epidemiology, clinical features, and prevention and control of CCHF (12).

Methods

For this paper, we conducted a focused review of National Center for Biotechnology's MeSH (Medical Subject Headings, <https://www.ncbi.nlm.nih.gov/mesh>) and PubMed (<https://pubmed.ncbi.nlm.nih.gov>) search strings customized for CCHF and CCHFV. We focused our review on the past 10 years and on human data, when available. We included older relevant data and animal data where appropriate. We conducted title, abstract, and full text reviews of relevant manuscripts, reviews, and book chapters. We also completed bibliography scans on review articles and meta-analyses.

Diagnostic Testing

The nonspecific CCHF characteristics make a high index of suspicion, on the basis of epidemiologic history, clinical signs and symptoms, and initial laboratory findings, key for early diagnosis and initiation of aggressive treatment. Delays in diagnosis and hospitalization are common and have occurred in up to 68% of patients in Turkey and led to increased mortality rates when compared with patients whose infections are diagnosed early (13).

Although many laboratory assays have been developed for diagnosing CCHF, the availability and Biosafety Level (BSL) requirements for safe specimen handling vary widely between countries. Sweden, Switzerland, France, Germany, Italy, and the United Kingdom recommend BSL-4 for CCHFV diagnostic assays (14). Conversely, the United States, South Africa, Kazakhstan, Slovenia, and Georgia allow diagnostic tests to be performed in BSL-3 laboratories, and Bulgaria, Turkey, and Serbia recommend BSL-2 laboratories (15). For most testing modalities, other than viral culture, viral




Figure. Overview of Crimean-Congo hemorrhagic fever virus symptom onset, clinical course, and diagnostic testing timeframes. ALT, alanine aminotransferase; AST, aspartate aminotransferase; DIC disseminated intravascular coagulation; PLTs, platelets; PTSD, post-traumatic stress disorder; WBCs, white blood cells.

inactivation of the sample can be performed to downgrade the BSL requirement (16,17).

Diagnosis can be obtained either by viral detection or identification of an immune response against CCHFV (Table), and test selection is guided by clinical phase. Although most viral detection tests, either viral culture, nucleic acid amplification tests, or viral antigen detection assays, will have greater sensitivity than immunoassays for diagnosis during the prehemorrhagic or early hemorrhagic phases, serologic testing is reserved for a delayed diagnosis or beyond day 5 after symptom onset (17) (Table; Figure). If a negative antibody test is obtained during the second week of illness in a patient suspected to have CCHF, a direct viral assay might be warranted for diagnostic clarification (17). Undetectable IgM and IgG in CCHF patients with fatal outcomes have been described (9). Whether those patients succumbed to CCHF because of failure to mount an antibody response, a rapidly progressive clinical course with fatal outcome before day 7, or formation of immune complexes that made antibodies undetectable is unclear (9).

Direct viral detection tests are useful during viremic stages of CCHF. Viral cultures using cell lines or intracerebral inoculation of suckling mice can detect a wide diversity of CCHFV strains; however, viral cultures are time-consuming,

and results can take several days. Another challenge is the paucity of BSL-3 and BSL-4 laboratories able to safely perform viral cultures in endemic areas (17). Nucleic acid amplification tests, such as reverse transcription PCR (RT-PCR), can be useful for diagnosis until up to days 10–12 of illness. Assays can be run in inactivated samples in BSL-2 and BSL-3 facilities, but correct inactivation methods need to be selected for compatibility with the chosen diagnostic test (15,16). Some of those assays are designed as multiplex assays instead of CCHFV-specific and provide breadth to rule out other viral hemorrhagic fevers (17). Assays capable to detecting viral load also are available (17). However, accuracy of those tests varies and is affected by the match between the PCR primers used and the viral strain because of the wide genetic diversity of CCHFV (17). Accuracy can be improved by using real-time RT-PCR (rRT-PCR) or a combination of rRT-PCR and conventional RT-PCR or rRT-PCR and nested RT-PCR (17). Combining assays can increase accuracy to 80% from 66% of reference samples when using conventional RT-PCR alone and from 46% when using nested RT-PCR alone (17).

Viral antigen detection tests, such as ELISA for serum or immunohistochemistry for tissue from biopsies or autopsy samples, also can be used early in the disease. Those assays require a lower level

of laboratory sophistication, can be done on inactivated samples, and offer timely results; however, assay sensitivity decreases as antibodies become detectable. IgM can be detectable as early as 4–5 days and usually by 7–9 days after symptom onset, peaks within 2–3 weeks, and declines to an almost undetectable level by month 4 from symptom onset (9,16,17). IgG typically becomes detectable 1–2 days after IgM (usually 7–9 days after illness onset), peaking in some patients between weeks 2–3 and between 2–5 months in some other patients. IgG remains detectable for at least 3 years (9,16,17). Neutralizing antibodies, although not routinely tested in the clinical setting, often can be detected by day 10 with variable titers (9).

CCHF diagnosis can be confirmed not only by the direct viral identification methods described, but also by evidence of a serologic response consistent with acute infection. CCHFV serologic testing is typically recommended 5–7 days after symptom onset; ELISA and immunofluorescence assays are the most common (16) (Figure). ELISA results are considered consistent with acute infection if either

CCHFV IgM is detected or a 4-fold increase in CCHFV IgG titers occurs between serial blood samples. Some CCHFV antibody assays are known to cross-react with Nairobi sheep disease serogroup, which also causes human disease in some CCHF endemic areas, and with Hazara virus, a member of the CCHFV group with no documented human disease (18). Several ELISA kits are commercially available for research but not for clinical diagnostic testing, and their sensitivity and specificity are also susceptible to CCHFV genetic variability (16). However, some of those assays have sensitivities >80% and specificities close to 100% (17). One commercially available immunofluorescence assay demonstrated a sensitivity of 93.9% for IgM and 86% for IgG and 100% specificity for both (17) (Table). No commercial rapid CCHF diagnostic tests are available for clinical use (16,17,19).

In the United States, testing of clinical specimens for CCHFV at designated reference laboratories should be arranged by consulting with respective local public health authorities and coordinating with the Centers for Disease Control and Prevention.

Table. Advantages and disadvantages of various diagnostic tests for CCHFV*

Test selection	Timing	Advantages	Disadvantages
Viral detection†			
Viral culture‡	Early after symptom onset	Detects a wide diversity of CCHFV strains	Requires BSL-3 or BSL-4 laboratory, which are not readily available in endemic areas. Requires several days to yield a result.
NAAT, RT-PCR	≤10–12 days after symptom onset	If samples are inactivated, then NAAT can be run in BSL-2 or BSL-3 facilities. Several multiplex assays available, and some can quantify viral load.	Variable sensitivity depending on match between primers and infecting strain. Sensitivity and specificity can vary by geographic region. Better sensitivity (80%) when PCR combinations used, e.g., rRT-PCR and conventional PCR or rRT-PCR and nested PCR (17).
Viral antigen detection			
ELISA	≤5–9 days after symptom onset	Timely results. Viral inactivation can be performed. Requires less laboratory specialization.	Decreased sensitivity after CCHFV antibodies are detectable.
Immunohistochemistry	≤5–9 days after symptom onset	Can assist in retrospective diagnosis for fatal cases.	Requires biopsy or necropsy samples.
Immune response, serology			
IgM ELISA§ or IFA¶	Detectable 7–9 days after symptom onset; peak 2–3 weeks; declines to low levels by month 4	ELISA sensitivity 87.8%, specificity 98.9. IFA sensitivity 93.9%, specificity 100% (17).	Commercially available kits for research but not for clinical laboratories; variable geographic sensitivity; IgM might not be detectable in fatal cases
IgG ELISA§, IFA¶, or Luminex xMAP	Detectable 1–2 d after IgM, peaks 2 wks–5 mo; detectable for <3 y	ELISA sensitivity 80.4%, specificity 100%. IFA sensitivity 86.1% specificity 100% (17).	Commercial ELISA and IFA kits available for research but not for clinical laboratories; variable geographic sensitivity; IgM might not be detectable in fatal cases
Neutralizing antibodies#	≥10 days after illness onset	Can be performed in BSL-2 facilities	Takes several days to perform. Not routinely used for diagnostic purposes.

*BSL, Biosafety Level; CCHFV, Crimean-Congo hemorrhagic fever virus; RT-PCR, reverse transcription PCR; rRT-PCR, real-time RT-PCR; Ddx, differential diagnoses; IFA: immunofluorescence assays; Nabs, neutralizing antibodies.

†Recommended when patient is viremic. Could be performed as cell culture or intracerebral inoculation of mice.

‡RT-PCR could be real-time, conventional, nested or a combination

§VectroCrimea-CHF (Vector-Best, <https://en.vector-best.ru>).

¶Crimean Congo Fever Mosaic 2 (Euroimmun, <https://www.euroimmun.com>).

#Pseudoplaque or plaque reduction neutralization tests for CCHFV viral-like particles.

CCHFV is a notifiable communicable disease in the United States and Europe and is considered a category A priority pathogen by the National Institute of Allergy and Infectious Diseases (NIAID; <https://www.niaid.nih.gov/research/emerging-infectious-diseases-pathogens>). Thus, clinicians should coordinate with public health authorities for collecting and shipping clinical samples and should follow requirements by the US Department of Transportation Hazardous Materials Regulations, 49 CFR 171–180 (<https://www.ecfr.gov/current/title-49/subtitle-B/chapter-I/subchapter-C>), and the International Air Transport Association Dangerous Goods Regulations (<https://www.iata.org/en/publications/dgr>).

Medical Countermeasures

No FDA-approved medications or vaccines are available to prevent or treat CCHF, nor are any approved by the European Medicines Agency. In this section, we describe evidence for off-label use of existing medications and upcoming investigational countermeasures that are in development and have been assessed for prophylactic or therapeutic effects on CCHFV infection in humans or animal models. The first article in this series should serve as a reference on virologic features when reviewing medical countermeasures and vaccine sections (11).

Preexposure Prophylaxis and CCHF Vaccines

A single vaccine is available to prevent CCHF in humans, produced by BulBio-NCIPD Limited (<https://www.bulbio.com>), but its licensure is limited to Bulgaria. This vaccine originally was developed in the former Soviet Union in 1970 and has been used in at-risk populations in Bulgaria, primarily military and medical personnel, since 1974 (20). The vaccine consists of chloroform and heat inactivated CCHFV strain V42/81 isolated from suckling mouse brain tissue (20). The vaccine series is administered in 2 intramuscular doses 30 days apart, a 3rd dose at 1 year, and subsequent booster doses every 5 years (20). The vaccine has been shown to elicit CCHFV IgG but with low viral neutralization activity and T-cell responses to the CCHFV nucleoprotein (21). No vaccine effectiveness data are available. A 4-fold decrease in CCHFV diagnoses in Bulgaria was demonstrated in the 21 years after introduction of that vaccine; however, the degree to which the decrease is attributable to vaccination versus other measures remains unclear (20).

Aside from the inactivated vaccine available in Bulgaria, only 1 vaccine candidate, an inactivated vaccine derived from cell culture, has advanced to

human clinical trials (<https://www.ClinicalTrials.gov>, no. NCT03020771). Although a phase 1 trial has been completed, no results were available by early 2023. Several other vaccine candidates are in preclinical development. Those vaccines primarily target the CCHFV glycoprotein, nucleoprotein, or both, including DNA-based (22–29), RNA-based (30,31), protein subunit-based (32–34), viral replicon particle-based platforms (35–38), and recombinant viral vector-based platforms that use bovine herpesvirus type 4, human adenovirus 5, modified vaccinia Ankara, and vesicular stomatitis virus (39–44). Vaccine-induced protection might be elicited by vaccines containing either the CCHFV glycoprotein or nucleoprotein in preclinical studies, but not consistently across vaccine platforms expressing the same antigen (Appendix 1 Table, <https://wwwnc.cdc.gov/EID/article/30/5/23-1648-App1.pdf>).

The World Health Organization has identified development of CCHF vaccines as a priority (45) but faces multiple challenges, including the high degree of genetic diversity between CCHFV strains, the need for high biocontainment laboratories to perform challenge studies, and the limited animal models in which CCHF disease can be replicated. Animal models amenable to vaccine studies were not available until lethal CCHF disease models in mice with deficits in type 1 interferon signaling pathways (STAT1^{-/-} and IFNAR^{-/-} mice) were identified in 2010 (46,47). Recently developed models of CCHF disease in humanized mice, in cynomolgus macaques (*Macaca fascicularis*), and among immunocompetent mice using a mouse-adapted CCHFV variant provide additional options for future CCHF vaccine studies (48–50). The lack of immune correlates of protection against CCHFV additionally poses a challenge for vaccine development. Neither CCHFV antibody titers nor neutralizing antibody titers correlate with vaccine-induced protection against disease or survival in animal models (9,10,25,26,32,43). However, recent data from a novel repRNA vaccine expressing CCHFV nucleoprotein suggest that a single dose of this vaccine could induce robust and protective immunity in mice (30). Some studies suggest that both humoral and cellular immune responses might be required for full protection against CCHF disease and death (30,42).

Postexposure Prophylaxis

Ribavirin (1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) is a purine nucleoside analog that acts against a wide range of viruses (Appendix 2 [<https://wwwnc.cdc.gov/EID/article/30/5/23-1648-App2.pdf>]) references

51,52). Ribavirin has multiple potential mechanisms of antiviral activity and in vitro antiviral activity against CCHFV (Appendix 2 references 51,52). The effectiveness of oral ribavirin prophylaxis for preventing CCHF is unknown, but it has been used as postexposure prophylaxis among healthcare workers with known CCHFV exposures (Appendix 2 references 53–56). The optimal dosing and duration of postexposure prophylaxis is unclear; postexposure ribavirin regimens reported to date for CCHFV include total doses ranging from 1,200 to 4,000 mg daily and doses administered from 2 to 4 times daily for 5–14 days, with or without a loading dose (21) (Appendix 2 references 53–57). CCHFV seroconversion has been reported among healthcare workers who were administered postexposure ribavirin prophylaxis after sustaining breaches in personal protective equipment while managing CCHF patients (Appendix 2 references 54,58). Mild symptoms in those healthcare workers initially were attributed to side effects from ribavirin (Appendix 2 references 54,58). Ribavirin frequently causes side effects, including fatigue, gastrointestinal symptoms, headache, hemolytic anemia, and laboratory abnormalities (Appendix 2 references 54,55). Ribavirin is contraindicated during pregnancy and has an FDA category X rating because of potential embryotoxic and teratogenic effects (Appendix 2 reference 59).

Antiviral Drug Treatments

Ribavirin

In addition to postexposure prophylaxis, ribavirin has been used to treat CCHF. Ribavirin reduces CCHFV viral loads in murine models (Appendix 2 references 60,61). However, similar viremia reductions have not been observed among infected humans treated with ribavirin compared with untreated control patients (Appendix 2 references 62,63).

Evidence from human studies of ribavirin for CCHF treatment mainly consists of case series, case-control studies that use historical controls, and retrospective analyses, but few randomized clinical trials have been conducted, and meta-analyses identified potential for bias in multiple studies (Appendix 2 references 64–67). In addition to variable study design, comparison of ribavirin effectiveness across studies is challenging because study outcomes could be influenced by other heterogeneous factors, such as differences in the administration route (oral vs. intravenous) and dosing of ribavirin, timing of ribavirin initiation, co-administration of other potential disease-modifying medications, severity of patients analyzed, and

variation in predominant CCHFV strains in different geographic regions.

A prospective, randomized clinical trial of oral ribavirin for CCHF treatment conducted in Turkey compared ribavirin with supportive therapy alone (Appendix 2 reference 68). In that study, patients were administered 30 mg/kg ribavirin as a loading dose, then 15 mg/kg every 6 hours for 4 days, after which they received 7.5 mg/kg every 8 hours for 6 days. The researchers observed no substantial differences in death, hospitalization duration, time to normalization of transaminases, or percentage of patients requiring platelet transfusions (Appendix 2 reference 68). Several meta-analyses reveal mixed results for effects of ribavirin on CCHF, ranging from no clear survival benefit to a 1.7-fold reduction in mortality rates among CCHF patients treated with ribavirin compared with those not receiving ribavirin (Appendix 2 reference 64–67).

Favipiravir

Favipiravir (6-fluoro-3-hydroxy-2-pyrazinecarboxamide) is a pyrazine analog that inhibits RNA polymerase activity in a wide variety of viruses. In vitro studies suggest that premature chain termination induced by favipiravir exceeds that of ribavirin for CCHFV and demonstrate synergistic antiviral effects when ribavirin and favipiravir are combined (Appendix 2 references 69,70).

Favipiravir is not licensed for use in the United States but is licensed for treatment of novel influenza A in Japan. Early favipiravir treatment for CCHFV infection reduces viral loads and clinical signs in both murine and macaque CCHF models, but prolonged viral detection and occasional late-onset CCHF disease were observed in mice (Appendix 2 references 60,71). In lethal CCHFV challenge mouse models, treatment with favipiravir enhanced disease survival, even when initiated as late as 6 days postinfection (Appendix 2 references 60,70). Only 1 case of human CCHF treatment with favipiravir has been described: a patient hospitalized with CCHFV and SARS-CoV-2 co-infection was treated with 1,600 mg favipiravir twice daily on day 1, then 600 mg twice daily for 4 days; the patient subsequently recovered (Appendix 2 reference 72). Favipiravir induces teratogenicity in animal models and should be avoided in pregnant and lactating women, if possible. Additional adverse effects include the potential for gastrointestinal distress (e.g., nausea, vomiting, or diarrhea), increased bilirubin levels, transaminitis, QTc prolongation, and hyperuricemia (Appendix 2 reference 73).

Other Treatments

Supportive therapy remains the mainstay of CCHF treatment. Such therapy includes fluid replacement, management of electrolyte disturbances, blood product replacement for critically low levels and coagulopathy (e.g., fresh frozen plasma, packed red blood cells, or platelets), treatment of secondary infections, and external support for organ dysfunction (e.g., hemodialysis, mechanical ventilation) when necessary (Appendix 2 references 74–77). Aspirin and nonsteroidal antiinflammatory drugs should be avoided because of the potential inhibition of platelet aggregation or agglutination.

Therapeutic plasma exchange and plasmapheresis have been used to treat CCHF, but the clinical benefits of those measures remain unclear because data are limited to individual case reports or small case series (Appendix 2 references 78–81). In patients with CCHF-related hemophagocytic lymphohistiocytosis, use of intravenous immunoglobulin or high dose steroids, in addition to blood product transfusions, has been reported (Appendix 2 references 82,83). In a study of 35 CCHF patients in Iran, high dose methylprednisolone (10 mg/kg for 3 days, followed by 5 mg/kg for 2 days) administered with ribavirin to patients with platelet counts <50,000/mL resulted in higher platelet and leukocyte counts and decreased need for transfusions compared with ribavirin alone, but no difference in deaths was observed (Appendix 2 reference 84). In 1 retrospective study, fewer deaths were observed among patients with severe CCHF who received both corticosteroids and ribavirin therapy compared with those treated with ribavirin alone, but no statistically significant decrease in deaths was observed among patients with mild or moderate CCHF treated with this combination (Appendix 2 reference 85). In 1 meta-analysis, an additional decrease in deaths was observed for corticosteroids in addition to ribavirin compared with ribavirin alone (Appendix 2 reference 65).

Hyperimmune immunotherapy for CCHF using pooled serum or plasma harvested from CCHF survivors or CCHF vaccine recipients has been reported, but its effectiveness is unknown because its use has only been reported in small case series (Appendix 2 references 86–88). Hyperimmune serum for CCHF treatment is not approved by either the FDA or the European Medicines Agency. Monoclonal antibodies for CCHF are in preclinical development and show improved survival among mouse models, but the degree of protection conferred by some monoclonal antibodies varied

depending on the infecting CCHFV strain (Appendix 2 references 89,90).

Conclusion

CCHFV poses a continued public health threat given its wide geographic distribution, potential to spread to new regions, propensity for genetic variability, and potential for severe and fatal illness. Although infection control measures can be effective in reducing the risk for CCHFV transmission within community and healthcare settings, those measures require correct and consistent application. An urgent need exists for new CCHF diagnostic tests, prophylaxes, and treatments. The current lack of licensed effective therapeutic and prophylactic drugs, gaps in our understanding of CCHFV pathogenesis and immunology, and slow progression in development of CCHF medical countermeasures are in part related to the dearth of animal models and high level of biosafety precautions needed to safely work with CCHFV.

In conclusion, to promptly diagnose CCHF, clinicians should have a high index of suspicion, collect a comprehensive travel and epidemiologic history, and perform a thorough clinical evaluation. Evidence to demonstrate human benefit from off-label use of ribavirin and favipiravir is disparate. Because few medical countermeasures are available for prophylaxis and treatment, supportive care remains the treatment standard for CCHF disease management. New CCHF diagnostic tests, prophylaxis, and treatments are urgently needed. Given its wide range and potential for severe outcomes, clinicians should become familiar with available diagnostic and management tools for CCHFV infections in humans.

Members of the State of the Clinical Science Working Group of the National Emerging Pathogens Training and Education Center's Special Pathogens Research Network: Richard T. Davey, Jr., Noreen A. Hynes, Mark G. Kortepeter, Nahid Bhadelia, Kerry Dierberg, Aneesh K. Mehta, Corri B. Levine, Peter C. Iwen, Denis A. Bente, Justin Chan, and Adam Beitscher.

Acknowledgments

We thank Nahid Bhadelia, Kerry Dierberg, and Mark G. Kortepeter for completing a previous version of this manuscript.

Research reported in this publication was supported by the Department of Health and Human Services Office of the Assistant Secretary for Preparedness and Response.

About the Author

Dr. Frank is a hospitalist and medical director of Denver Health Hospital Authority's Biocontainment Unit and a professor of medicine at the University of Colorado, School of Medicine, Denver, CO, USA. Her research interests include medical management of special pathogens and involvement of general internists in disaster response.

References

- Ergonul O, Whitehouse CA, eds. Crimean-Congo hemorrhagic fever: a global perspective. Dordrecht (The Netherlands): Springer; 2007.
- Mishra AK, Hellert J, Freitas N, Guardado-Calvo P, Haouz A, Fels JM, et al. Structural basis of synergistic neutralization of Crimean-Congo hemorrhagic fever virus by human antibodies. *Science*. 2022;375:104–9. <https://doi.org/10.1126/science.abl6502>
- World Health Organization. Introduction to Crimean Congo haemorrhagic fever: managing infectious hazards [cited 2023 Jul 1]. <https://cdn.who.int/media/docs/default-source/documents/health-topics/crimean-congo-haemorrhagic-fever/introduction-to-crimean-congo-haemorrhagic-fever.pdf>
- Al-Abri SS, Abaidani IA, Fazlalipour M, Mostafavi E, Leblebicioglu H, Pshenichnaya N, et al. Current status of Crimean-Congo haemorrhagic fever in the World Health Organization Eastern Mediterranean Region: issues, challenges, and future directions. *Int J Infect Dis*. 2017;58:82–9. <https://doi.org/10.1016/j.ijid.2017.02.018>
- Hawman DW, Feldmann H. Recent advances in understanding Crimean-Congo hemorrhagic fever virus. *F1000 Res*. 2018;7:1715. <https://doi.org/10.12688/f1000research.16189.1>
- Khan AS, Maupin GO, Rollin PE, Noor AM, Shurie HHM, Shalabi AGA, et al. An outbreak of Crimean-Congo hemorrhagic fever in the United Arab Emirates, 1994–1995. *Am J Trop Med Hyg*. 1997;57:519–25. <https://doi.org/10.4269/ajtmh.1997.57.519>
- Nurettin C, Engin B, Sukru T, Munir A, Zati V, Aykut O. The seroprevalence of Crimean-Congo hemorrhagic fever in wild and domestic animals: an epidemiological update for domestic animals and first serovidence in wild animals from Türkiye. *Vet Sci*. 2022;9:462. <https://doi.org/10.3390/vetsci9090462>
- Saksida A, Duh D, Wraber B, Dedushaj I, Ahmeti S, Avsic-Zupanc T. Interacting roles of immune mechanisms and viral load in the pathogenesis of Crimean-Congo hemorrhagic fever. *Clin Vaccine Immunol*. 2010;17:1086–93. <https://doi.org/10.1128/CVI.00530-09>
- Rodriguez SE, Hawman DW, Sorvillo TE, O'Neal TJ, Bird BH, Rodriguez LL, et al. Immunobiology of Crimean-Congo hemorrhagic fever. *Antiviral Res*. 2022; 199:105244. <https://doi.org/10.1016/j.antiviral.2022.105244>
- Garrison AR, Smith DR, Golden JW. Animal models for Crimean-Congo hemorrhagic fever human disease. *Viruses*. 2019;11:590. <https://doi.org/10.3390/v11070590>
- Frank MG, Weaver G, Raabe V; State of the Clinical Science Working Group of the National Emerging pathogens Training and Education Center's Special Pathogens Research Network. Crimean-Congo hemorrhagic fever virus for clinicians – epidemiology, clinical manifestations, and prevention. *Emerg Infect Dis*. 2024;30:854–863. <https://doi.org/10.3201/eid3005.231647>
- Tasdelen Fisgin N, Doganci L, Tanyel E, Tulek N. Initial high rate of misdiagnosis in Crimean Congo haemorrhagic fever patients in an endemic region of Turkey. *Epidemiol Infect*. 2010;138:139–44. <https://doi.org/10.1017/S0950268809990318>
- Fletcher TE, Gulzhan A, Ahmeti S, Al-Abri SS, Asik Z, Atilla A, et al. Infection prevention and control practice for Crimean-Congo hemorrhagic fever – a multi-center cross-sectional survey in Eurasia. *PLoS One*. 2017; 12:e0182315. <https://doi.org/10.1371/journal.pone.0182315>
- Weidmann M, Avsic-Zupanc T, Bino S, Bouloy M, Burt F, Chinikar S, et al. Biosafety standards for working with Crimean-Congo hemorrhagic fever virus. *J Gen Virol*. 2016;97:2799–808. <https://doi.org/10.1099/jgv.0.000610>
- Emmerich P, von Possel R, Deschermeier C, Ahmeti S, Berisha L, Halili B, et al. Comparison of diagnostic performances of ten different immunoassays detecting anti-CCHFV IgM and IgG antibodies from acute to subsided phases of Crimean-Congo hemorrhagic fever. *PLoS Negl Trop Dis*. 2021;15:e0009280. <https://doi.org/10.1371/journal.pntd.0009280>
- Raabe VN. Diagnostic testing for Crimean-Congo hemorrhagic fever. *J Clin Microbiol*. 2020;58:e01580-19. <https://doi.org/10.1128/JCM.01580-19>
- Suda Y, Chamberlain J, Dowall SD, Saijo M, Horimoto T, Hewson R, et al. The development of a novel diagnostic assay that utilizes a pseudotyped vesicular stomatitis virus for the detection of neutralizing activity against Crimean-Congo hemorrhagic fever virus. *Jpn J Infect Dis*. 2018;71:205–8. <https://doi.org/10.7883/yoken.JJID.2017.354>
- Mattiuzzo G, Bentley EM, Page M. The role of reference materials in the research and development of diagnostic tools and treatments for haemorrhagic fever viruses. *Viruses*. 2019;11:781. <https://doi.org/10.3390/v11090781>
- Papa A, Papadimitriou E, Christova I. The Bulgarian vaccine Crimean-Congo haemorrhagic fever virus strain. *Scand J Infect Dis*. 2011;43:225–9. <https://doi.org/10.3109/00365548.2010.540036>
- Mousavi-Jazi M, Karlberg H, Papa A, Christova I, Mirazimi A. Healthy individuals' immune response to the Bulgarian Crimean-Congo hemorrhagic fever virus vaccine. *Vaccine*. 2012;30:6225–9. <https://doi.org/10.1016/j.vaccine.2012.08.003>
- Spik K, Shurtleff A, McElroy AK, Guttieri MC, Hooper JW, SchmalJohn C. Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. *Vaccine*. 2006;24:4657–66. <https://doi.org/10.1016/j.vaccine.2005.08.034>
- Garrison AR, Shoemaker CJ, Golden JW, Fitzpatrick CJ, Suschak JJ, Richards MJ, et al. A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models. *PLoS Negl Trop Dis*. 2017;11:e0005908. <https://doi.org/10.1371/journal.pntd.0005908>
- Aligholipour Farzani T, Hanifehnezhad A, Földes K, Ergünay K, Yilmaz E, Hashim Mohamed Ali H, et al. Co-delivery effect of CD24 on the immunogenicity and lethal challenge protection of a DNA vector expressing

- nucleocapsid protein of Crimean Congo hemorrhagic fever virus. *Viruses*. 2019;11:75. <https://doi.org/10.3390/v11010075>
25. Hinkula J, Devignot S, Åkerström S, Karlberg H, Watrang E, Bereczky S, et al. Immunization with DNA plasmids coding for Crimean-Congo hemorrhagic fever virus capsid and envelope proteins and/or virus-like particles induces protection and survival in challenged mice. *J Virol*. 2017;91:e02076-16. <https://doi.org/10.1128/JVI.02076-16>
 26. Suschak JJ, Golden JW, Fitzpatrick CJ, Shoemaker CJ, Badger CV, Schmaljohn CS, et al. A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice. *NPJ Vaccines*. 2021;6:31. <https://doi.org/10.1038/s41541-021-00293-9>
 27. Hawman DW, Meade-White K, Leventhal S, Appelberg S, Ahlén G, Nikouyan N, et al. Accelerated DNA vaccine regimen provides protection against Crimean-Congo hemorrhagic fever virus challenge in a macaque model. *Mol Ther*. 2023;31:387-97. <https://doi.org/10.1016/j.ymthe.2022.09.016>
 28. Hawman DW, Ahlén G, Appelberg KS, Meade-White K, Hanley PW, Scott D, et al. A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a cynomolgus macaque model. *Nat Microbiol*. 2020;6:187-95. <https://doi.org/10.1038/s41564-020-00815-6>
 29. Hu YL, Zhang LQ, Liu XQ, Ye W, Zhao YX, Zhang L, et al. Construction and evaluation of DNA vaccine encoding Crimean Congo hemorrhagic fever virus nucleocapsid protein, glycoprotein N-terminal and C-terminal fused with LAMP1. *Front Cell Infect Microbiol*. 2023;13:1121163. <https://doi.org/10.3389/fcimb.2023.1121163>
 30. Leventhal SS, Meade-White K, Rao D, Haddock E, Leung J, Scott D, et al. Replicating RNA vaccination elicits an unexpected immune response that efficiently protects mice against lethal Crimean-Congo hemorrhagic fever virus challenge. *EBioMedicine*. 2022;82:104188. <https://doi.org/10.1016/j.ebiom.2022.104188>
 31. Appelberg S, John L, Pardi N, Végvári Á, Bereczky S, Ahlén G, et al. Nucleoside-modified mRNA vaccines protect IFNAR^{-/-} mice against Crimean-Congo hemorrhagic fever virus infection. *J Virol*. 2022;96:e0156821. <https://doi.org/10.1128/jvi.01568-21>
 32. Kortekaas J, Vloet RP, McAuley AJ, Shen X, Bosch BJ, de Vries L, et al. Crimean-Congo Hemorrhagic fever virus subunit vaccines induce high levels of neutralizing antibodies but no protection in STAT1 knockout mice. *Vector Borne Zoonotic Dis*. 2015;15:759-64. <https://doi.org/10.1089/vbz.2015.1855>
 33. Wang Q, Wang S, Shi Z, Li Z, Zhao Y, Feng N, et al. GEM-PA-based subunit vaccines of Crimean Congo hemorrhagic fever induces systemic immune responses in mice. *Viruses*. 2022;14:1664. <https://doi.org/10.3390/v14081664>
 34. Ghiasi SM, Salmanian AH, Chinikar S, Zakeri S. Mice orally immunized with a transgenic plant expressing the glycoprotein of Crimean-Congo hemorrhagic fever virus. *Clin Vaccine Immunol*. 2011;18:2031-7. <https://doi.org/10.1128/CVI.05352-11>
 35. Scholte FEM, Spengler JR, Welch SR, Harmon JR, Coleman-McCray JD, Freitas BT, et al. Single-dose replicon particle vaccine provides complete protection against Crimean-Congo hemorrhagic fever virus in mice. *Emerg Microbes Infect*. 2019;8:575-8. <https://doi.org/10.1080/22221751.2019.1601030>
 36. Spengler JR, Welch SR, Scholte FEM, Coleman-McCray JD, Harmon JR, Nichol ST, et al. Heterologous protection against Crimean-Congo hemorrhagic fever in mice after a single dose of replicon particle vaccine. *Antiviral Res*. 2019;170:104573. <https://doi.org/10.1016/j.antiviral.2019.104573>
 37. Tipih T, Heise M, Burt FJ. Immunogenicity of a DNA-based Sindbis replicon expressing Crimean-Congo hemorrhagic fever virus nucleoprotein. *Vaccines (Basel)*. 2021;9:1491. <https://doi.org/10.3390/vaccines9121491>
 38. Spengler JR, Welch SR, Scholte FEM, Rodriguez SE, Harmon JR, Coleman-McCray JD, et al. Viral replicon particles protect IFNAR^{-/-} mice against lethal Crimean-Congo hemorrhagic fever virus challenge three days after vaccination. *Antiviral Res*. 2021;191:105090. <https://doi.org/10.1016/j.antiviral.2021.105090>
 39. Aligholipour Farzani T, Földes K, Hanifnezhad A, Yener Ilce B, Bilge Dagalp S, Amirzadeh Khiabani N, et al. Bovine herpesvirus type 4 (BoHV-4) vector delivering nucleocapsid protein of Crimean-Congo hemorrhagic fever virus induces comparable protective immunity against lethal challenge in IFN α / β / γ R^{-/-} mice models. *Viruses*. 2019;11:237. <https://doi.org/10.3390/v11030237>
 40. Zivcec M, Safronetz D, Scott DP, Robertson S, Feldmann H. Nucleocapsid protein-based vaccine provides protection in mice against lethal Crimean-Congo hemorrhagic fever virus challenge. *PLoS Negl Trop Dis*. 2018;12:e0006628. <https://doi.org/10.1371/journal.pntd.0006628>
 41. Buttigieg KR, Dowall SD, Findlay-Wilson S, Miloszewska A, Rayner E, Hewson R, et al. A novel vaccine against Crimean-Congo haemorrhagic fever protects 100% of animals against lethal challenge in a mouse model. *PLoS One*. 2014;9:e91516. <https://doi.org/10.1371/journal.pone.0091516>
 42. Dowall SD, Graham VA, Rayner E, Hunter L, Watson R, Taylor I, et al. Protective effects of a modified vaccinia Ankara-based vaccine candidate against Crimean-Congo haemorrhagic fever virus require both cellular and humoral responses. *PLoS One*. 2016;11:e0156637. <https://doi.org/10.1371/journal.pone.0156637>
 43. Dowall SD, Buttigieg KR, Findlay-Wilson SJ, Rayner E, Pearson G, Miloszewska A, et al. A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease. *Hum Vaccin Immunother*. 2016;12:519-27. <https://doi.org/10.1080/21645515.2015.1078045>
 44. Rodriguez SE, Cross RW, Fenton KA, Bente DA, Mire CE, Geisbert TW. Vesicular stomatitis virus-based vaccine protects mice against Crimean-Congo hemorrhagic fever. *Sci Rep*. 2019;9:7755. <https://doi.org/10.1038/s41598-019-44210-6>
 45. Mehand MS, Al-Shorbaji F, Millett P, Murgue B. The WHO R&D Blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts. *Antiviral Res*. 2018;159:63-7. <https://doi.org/10.1016/j.antiviral.2018.09.009>
 46. Bente DA, Alimonti JB, Shieh WJ, Camus G, Ströher U, Zaki S, et al. Pathogenesis and immune response of Crimean-Congo hemorrhagic fever virus in a STAT-1 knockout mouse model. *J Virol*. 2010;84:11089-100. <https://doi.org/10.1128/JVI.01383-10>
 47. Bereczky S, Lindegren G, Karlberg H, Åkerström S, Klingström J, Mirazimi A. Crimean-Congo hemorrhagic fever virus infection is lethal for adult type I interferon receptor-knockout mice. *J Gen Virol*. 2010;91:1473-7. <https://doi.org/10.1099/vir.0.019034-0>


48. Spengler JR, Kelly Keating M, McElroy AK, Zivcec M, Coleman-McCray JD, Harmon JR, et al. Crimean-Congo hemorrhagic fever in humanized mice reveals glial cells as primary targets of neurological infection. *J Infect Dis*. 2017;216:1386–97. <https://doi.org/10.1093/infdis/jix215>
49. Haddock E, Feldmann F, Hawman DW, Zivcec M, Hanley PW, Saturday G, et al. A cynomolgus macaque model for Crimean-Congo haemorrhagic fever. *Nat Microbiol*. 2018;3:556–62. <https://doi.org/10.1038/s41564-018-0141-7>
50. Oimomi M, Ohkawa J, Saeki S, Baba S. The frequency of C5 + cholinesterase in the normal Japanese population. *Clin Chim Acta*. 1988;175:349–50. [https://doi.org/10.1016/0009-8981\(88\)90113-1](https://doi.org/10.1016/0009-8981(88)90113-1)

Address for correspondence: Maria G. Frank, University of Colorado Anschutz Medical Campus, Internal Medicine, 12401 E 17th Ave, Mailstop F-782, Aurora, CO 80045-2559, USA; email: maria.frank@dhha.org or maria.frank@cuanschutz.edu

January 2024

Fastidious Bacteria

- Efficacy of Unregulated Minimum Risk Products to Kill and Repel Ticks
- *Auritidibacter ignavus*, an Emerging Pathogen Associated with Chronic Ear Infections
- Incidence of Legionnaires' Disease among Travelers Visiting Hotels in Germany, 2015–2019
- Early-Onset Infection Caused by *Escherichia coli* Sequence Type 1193 in Late Preterm and Full-Term Neonates
- Molecular Evolution and Increasing Macrolide Resistance of *Bordetella pertussis*, Shanghai, 2016–2022
- Disease-Associated *Streptococcus pneumoniae* Genetic Variation
- Effect of 2020–21 and 2021–22 Highly Pathogenic Avian Influenza H5 Epidemics on Wild Birds, the Netherlands
- COVID-19–Related School Closures, United States, July 27, 2020–June 30, 2022
- Effectiveness of Vaccines and Antiviral Drugs in Preventing Severe and Fatal COVID-19, Hong Kong
- Costs of Digital Adherence Technologies for Tuberculosis Treatment Support, 2018–2021
- Doxycycline Prophylaxis for Skin and Soft Tissue Infections in Naval Special Warfare Trainees, United States
- Predictive Mapping of Antimicrobial Resistance for *Escherichia coli*, *Salmonella*, and *Campylobacter* in Food-Producing Animals in Europe, 2000–2021



- Excess Deaths Associated with Rheumatic Heart Disease, Australia, 2013–2017
- Delayed *Plasmodium falciparum* Malaria in Pregnant Patient with Sickle Cell Trait 11 Years after Exposure, Oregon, United States
- Genomic Diversity and Zoonotic Potential of *Brucella neotomae*
- Increased Peripheral Venous Catheter Bloodstream Infections during the COVID-19 Pandemic, Switzerland
- Emergence of Novel Norovirus GII.4 Strainson 3 Continents
- Avian Influenza A(H5N1) Neuraminidase Inhibition Antibodies in Healthy Adults after Exposure to Influenza A(H1N1)pdm09
- Clade I–Associated Mpox Cases Associated with Sexual Contact, the Democratic Republic of the Congo
- *Macacine Alphaherpesvirus 1* (B Virus) Infection in Humans, Japan, 2019
- Estimation of Incubation Period of Mpox during 2022 Outbreak in Pereira, Colombia
- Autochthonous Dengue Fever in 2 Patients, Rome, Italy
- *Pseudomonas guariconensis* Necrotizing Fasciitis, United Kingdom
- Rare *Spiroplasma* Bloodstream Infection in a Patient after Surgery
- Emergence of Dengue Virus Serotype 2 Cosmopolitan Genotype, Colombia
- Acute Gastroenteritis Associated with Norovirus GII.8[P8], Thailand, 2023
- Population-Based Study of Pertussis Incidence and Risk Factors among Persons >50 Years of Age, Australia
- Racial and Ethnic Disparities in Tuberculosis Incidence, Arkansas, USA, 2010–2021
- Reemergence of Human African Trypanosomiasis Caused by *Trypanosoma brucei rhodesiense*, Ethiopia
- *Helicobacter fennelliae* Localization to Diffuse Areas of Human Intestine, Japan
- A Cluster of Hantavirus Disease Cases Due to Infection by Seoul virus, Germany
- Tuberculosis Diagnostic Delays, Hospital Admissions, and Treatment Outcomes for Persons Also Diagnosed with COVID-19 within 120 days in California, 2020
- Respiratory Viruses in Wastewater Compared with Clinical Samples, Leuven, Belgium

**EMERGING
INFECTIOUS DISEASES**

To revisit the January 2024 issue, go to:
<https://wwwnc.cdc.gov/eid/articles/issue/30/1/table-of-contents>

EID cannot ensure accessibility for supplementary materials supplied by authors. Readers who have difficulty accessing supplementary content should contact the authors for assistance.

Crimean-Congo Hemorrhagic Fever Virus for Clinicians—Diagnosis, Clinical Management, and Therapeutics

Appendix 1

Appendix 1 Table. CCHF Vaccine Candidate Pre-Clinical Immunogenicity and Protection Results

CCHF antigen target	Vaccine type	No. doses; route	CCHFV IgG	CCHFV neutralizing antibodies	CCHFV T-cell response†	Protection against‡		Ref.
						Symptomatic disease	Lethal disease, % survival	
Gc only	DNA fused to lysosome-associated membrane protein 1	3; IM	Yes	Yes	Yes	NA	NA	Hu et al. (1)
	Protein subunit anchored to gram positive enhancer matrix	3; SC	Yes	Yes	Yes	NA	NA	Wang et al. (2)
	Protein subunit anchored to gram positive enhancer matrix with ISA201VG and PolyI:C adjuvant	3; SC	Yes	Yes	Yes	NA	NA	Wang et al. (2)
	Protein subunit with Sigma adjuvant system	2; IP	Yes	Yes	NA	No	0	Kortekaas et al. (3)
Gn only	DNA fused to lysosome-associated membrane protein 1	3; IM	Yes	Yes	Yes	NA	NA	Hu et al. (1)
	Protein subunit anchored to gram positive enhancer matrix	3; SC	Yes	No	Yes	NA	NA	Wang et al. (2)
	Protein subunit anchored to	3; SC	Yes	No	Yes	NA	NA	Wang et al. (2)

CCHF antigen target	Vaccine type	No. doses; route	CCHFV IgG	CCHFV neutralizing antibodies	CCHFV T-cell response†	Protection against‡		Ref.
						Symptomatic disease	Lethal disease, % survival	
	gram positive enhancer matrix with ISA201VG and PolyI:C adjuvant							
	Protein subunit with Sigma adjuvant system	2; IP	Yes	Yes	NA	No	NA	Kortekaas et al. (3)
Gc and Gn	Protein subunit produced in mosaic tobacco plants	5; oral	Yes§	NA	NA	NA	NA	Ghiasi et al. (4)
	Nucleoside-modified mRNA lipid nanoparticles	2; ID	Yes	Yes	Yes	Yes	100	Appelberg et al. (5)
	Ubiquitin-linked DNA	3; IM with electroporation	No	No	Yes	No	NA¶	Hawman et al. (6)
G-NAb (glycoprotein epitope spanning amino acids 1443–1566 on the M genome segment)	Protein subunit anchored to gram positive enhancer matrix	3; SC	Yes	No	Yes	NA	NA	Wang et al. (2)
	Protein subunit anchored to gram positive enhancer matrix with ISA201VG and PolyI:C adjuvant	3; SC	Yes	No	Yes	NA	NA	Wang et al. (2)
GP38 only	DNA	3; IM with electroporation	Yes	NA	NA	Partial	20	Suschak et al. (7)
M genome segment proteins except for GP38 and mucin-like domain	DNA	3; IM with electroporation	Yes	NA	NA	No	0	Suschak et al. (7)
All M genome segment proteins (all glycoprotein components and nonstructural proteins)	Alphavirus-based replicon RNA	2; IM	Possible (IgG antibodies in only 25% of vaccinated animals)	No	Yes	No	37.5	Leventhal et al. (8)
	DNA	3; transcutaneous via gene gun	Yes	~50%	NA	NA	NA	Spik et al. (9)

CCHF antigen target	Vaccine type	No. doses; route	CCHFV IgG	CCHFV neutralizing antibodies	CCHFV T-cell response†	Protection against‡		Ref.
						Symptomatic disease	Lethal disease, % survival	
	DNA	3; IM with electroporation	Yes	Yes	NA	Partial	>60	Garrison et al. (10)
	DNA	3; IM with electroporation	Yes	NA	Yes	No	80–100	Suschak et al. (7)
	Modified vaccinia Ankara vector	2; IM	Yes	NA	Yes	Yes	100	Buttigieg et al. (11) Dowall et al. (12)
	Vesicular stomatitis virus vector (replication incompetent)	2; IP	NA	NA	NA	No	0	Rodriguez et al. (13)
	Vesicular stomatitis virus vector (replication competent)	1; IP	Yes	Yes	NA	No	100	Rodriguez et al. (13)
	Vesicular stomatitis virus vector (replication competent)	2; IP	Yes	Yes	NA	Yes	100	Rodriguez et al. (13)
Nucleoprotein	Alphavirus-based replicon RNA	1; IM	Yes	NA	Yes (low levels)	Partial	100	Leventhal et al. (8)
	Alphavirus-based replicon RNA	2; IM	Yes	No	Yes (low levels)	Yes	100	Leventhal et al. (8)
	Bovine herpesvirus type 4 vector	2; IP	Yes	No	Yes	No	100	Farzani et al. (14)
	DNA fused to lysosome-associated membrane protein 1	3; IM	Yes	Yes	Yes	NA	NA	Hu et al. (1)
	DNA-based Sindbis virus replicon	3; IM	Yes	NA	Yes	NA	NA	Tipih et al. (15)
	DNA-based Sindbis virus replicon adjuvanted with PolyI:C	3; IM	Yes	NA	Yes	NA	NA	Tipih et al. (15)
	DNA adjuvanted with CD24	2; IM	Yes	No	Yes	Partial	100	Farzani et al. (16)
	DNA	2; IM	Yes	No	Yes	Partial	100	Farzani et al. (16)
	DNA	2; IM	Yes	No	Yes	No	75	Farzani et al. (14)
	Human adenovirus 5 vector	2; IP	Yes	No	Yes	No	100	Farzani et al. (14)

CCHF antigen target	Vaccine type	No. doses; route	CCHFV IgG	CCHFV neutralizing antibodies	CCHFV T-cell response†	Protection against‡		Ref.
						Symptomatic disease	Lethal disease, % survival	
Nucleoside-modified mRNA lipid nanoparticles		2; ID	Yes	No	Yes	Yes	100	Appelberg et al. (5)
	Modified vaccinia Ankara vector	2; IM	Yes	NA	Yes	No	0	Dowall et al. (12)
	Transcriptionally competent viral like particle	3; IM with electroporation	Yes	No	Yes	Yes	NA¶	Hawman et al. (17)
	Transcriptionally competent viral like particle	3; IP	Yes	Yes	NA	No	40	Hinkula et al. (18)
	Ubiquitin-linked DNA	2; IM with electroporation	Yes	No	Yes	No	NA¶	Hawman et al. (6)
	Ubiquitin-linked DNA	3; IM with electroporation	Yes	No	No	No	NA¶	Hawman et al. (6)
Nucleoprotein and all M genome segment proteins	Alphavirus-based replicon RNA	1; IM	Yes	NA	Yes	Yes	100	Leventhal et al. (8)
	Alphavirus-based replicon RNA	2; IM	Yes	No	Yes	Yes	100	Leventhal et al. (8)
Nucleoprotein, Gc, and Gn	Nucleoside-modified mRNA lipid nanoparticles	2; ID	Yes	Yes	Yes	Yes	100	Appelberg et al. (5)
	Ubiquitin-linked DNA	3; ID with electroporation	Yes	Yes	NA	Yes	100	Hinkula et al. (18)
All CCHF viral proteins	Viral replicon particle containing L and S genome segments#	1; SC	Yes	NA	NA	Yes	100	Spengler et al. (20)
			NA	NA	NA	Vaccinated ≥7 d before viral challenge: Yes. Vaccinated 3 d before viral challenge: Partial. Vaccinated 1 d before or after viral challenge: No	Vaccinated ≥3 d before viral challenge, 100. Vaccinated 1 d before or after viral challenge, 0	Spengler et al. (21)
			Yes	Yes	Yes	Partial	80–100	Berber et al. (22)
	Inactivated whole virus	3; IP	Yes	Yes	Yes	Partial	80–100	Berber et al. (22)

CCHF antigen target	Vaccine type	No. doses; route	CCHFV IgG	CCHFV neutralizing antibodies	CCHFV T-cell response†	Protection against‡		Ref.
						Symptomatic disease	Lethal disease, % survival	
	adjuvanted with alum derived from cell culture							Canakoglu et al. (23) Pavel et al. (24)

*CCHFV, Crimean-Congo hemorrhagic fever virus; ID, intradermal; IM, intramuscular; IP, intraperitoneal; SC, subcutaneous; NA, Not assessed.
†Direct measurement of CCHFV, CCHFV antigen-stimulated T-cell, or splenocyte responses only. Studies measuring serum cytokine levels post-vaccination were excluded.

‡For studies that assessed vaccine dosing ranges, the protection against symptomatic disease or lethal disease is presented only for the highest dose used.

§IgA antibodies were also detectable in serum and fecal pellets from vaccinated mice.

¶Unable to assess survival benefit due to non-lethal disease in the unvaccinated animal comparator study arm.

#The M genome segment is not contained in the viral replicon particle, however proteins from the M genome segment are provided *in trans* during the creation of the viral replicon particle leading to the incorporation of M genome segment proteins on the surface of the viral replicon particle.

References

1. Hu YL, Zhang LQ, Liu XQ, Ye W, Zhao YX, Zhang L, et al. Construction and evaluation of DNA vaccine encoding Crimean Congo hemorrhagic fever virus nucleocapsid protein, glycoprotein N-terminal and C-terminal fused with LAMP1. *Front Cell Infect Microbiol.* 2023;13:1121163. [PubMed https://doi.org/10.3389/fcimb.2023.1121163](https://doi.org/10.3389/fcimb.2023.1121163)
2. Wang Q, Wang S, Shi Z, Li Z, Zhao Y, Feng N, et al. GEM-PA–based subunit vaccines of Crimean Congo hemorrhagic fever induces systemic immune responses in mice. *Viruses.* 2022;14:1664. [PubMed https://doi.org/10.3390/v14081664](https://doi.org/10.3390/v14081664)
3. Kortekaas J, Vloet RP, McAuley AJ, Shen X, Bosch BJ, de Vries L, et al. Crimean-Congo Hemorrhagic fever virus subunit vaccines induce high levels of neutralizing antibodies but no protection in STAT1 knockout mice. *Vector Borne Zoonotic Dis.* 2015;15:759–64. [PubMed https://doi.org/10.1089/vbz.2015.1855](https://doi.org/10.1089/vbz.2015.1855)
4. Ghiasi SM, Salmanian AH, Chinikar S, Zakeri S. Mice orally immunized with a transgenic plant expressing the glycoprotein of Crimean-Congo hemorrhagic fever virus. *Clin Vaccine Immunol.* 2011;18:2031–7. [PubMed https://doi.org/10.1128/CVI.05352-11](https://doi.org/10.1128/CVI.05352-11)
5. Appelberg S, John L, Pardi N, Végvári Á, Bereczky S, Ahlén G, et al. Nucleoside-modified mRNA vaccines protect IFNAR^{-/-} mice against Crimean-Congo hemorrhagic fever virus infection. *J Virol.* 2022;96:e0156821. [PubMed https://doi.org/10.1128/jvi.01568-21](https://doi.org/10.1128/jvi.01568-21)
6. Hawman DW, Meade-White K, Leventhal S, Appelberg S, Ahlén G, Nikouyan N, et al. Accelerated DNA vaccine regimen provides protection against Crimean-Congo hemorrhagic fever virus challenge in a macaque model. *Mol Ther.* 2023;31:387–97. [PubMed https://doi.org/10.1016/j.ymthe.2022.09.016](https://doi.org/10.1016/j.ymthe.2022.09.016)

7. Suschak JJ, Golden JW, Fitzpatrick CJ, Shoemaker CJ, Badger CV, Schmaljohn CS, et al. A CCHFV DNA vaccine protects against heterologous challenge and establishes GP38 as immunorelevant in mice. *NPJ Vaccines*. 2021;6:31. [PubMed https://doi.org/10.1038/s41541-021-00293-9](https://doi.org/10.1038/s41541-021-00293-9)
8. Leventhal SS, Meade-White K, Rao D, Haddock E, Leung J, Scott D, et al. Replicating RNA vaccination elicits an unexpected immune response that efficiently protects mice against lethal Crimean-Congo hemorrhagic fever virus challenge. *EBioMedicine*. 2022;82:104188. [PubMed https://doi.org/10.1016/j.ebiom.2022.104188](https://doi.org/10.1016/j.ebiom.2022.104188)
9. Spik K, Shurtleff A, McElroy AK, Gutteri MC, Hooper JW, SchmalJohn C. Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. *Vaccine*. 2006;24:4657–66. [PubMed https://doi.org/10.1016/j.vaccine.2005.08.034](https://doi.org/10.1016/j.vaccine.2005.08.034)
10. Garrison AR, Shoemaker CJ, Golden JW, Fitzpatrick CJ, Suschak JJ, Richards MJ, et al. A DNA vaccine for Crimean-Congo hemorrhagic fever protects against disease and death in two lethal mouse models. *PLoS Negl Trop Dis*. 2017;11:e0005908. [PubMed https://doi.org/10.1371/journal.pntd.0005908](https://doi.org/10.1371/journal.pntd.0005908)
11. Buttigieg KR, Dowall SD, Findlay-Wilson S, Miloszewska A, Rayner E, Hewson R, et al. A novel vaccine against Crimean-Congo haemorrhagic fever protects 100% of animals against lethal challenge in a mouse model. *PLoS One*. 2014;9:e91516. [PubMed https://doi.org/10.1371/journal.pone.0091516](https://doi.org/10.1371/journal.pone.0091516)
12. Dowall SD, Graham VA, Rayner E, Hunter L, Watson R, Taylor I, et al. Protective effects of a modified vaccinia Ankara-based vaccine candidate against Crimean-Congo haemorrhagic fever virus require both cellular and humoral responses. *PLoS One*. 2016;11:e0156637. [PubMed https://doi.org/10.1371/journal.pone.0156637](https://doi.org/10.1371/journal.pone.0156637)
13. Rodriguez SE, Cross RW, Fenton KA, Bente DA, Mire CE, Geisbert TW. Vesicular stomatitis virus-based vaccine protects mice against Crimean-Congo hemorrhagic fever. *Sci Rep*. 2019;9:7755. [PubMed https://doi.org/10.1038/s41598-019-44210-6](https://doi.org/10.1038/s41598-019-44210-6)
14. Aligholipour Farzani T, Földes K, Hanifehnezhad A, Yener Ilce B, Bilge Dagalp S, Amirzadeh Khiabani N, et al. Bovine herpesvirus type 4 (BoHV-4) vector delivering nucleocapsid protein of Crimean-Congo hemorrhagic fever virus induces comparable protective immunity against lethal challenge in IFN α / β / γ R $^{-/-}$ mice models. *Viruses*. 2019;11:237. [PubMed https://doi.org/10.3390/v11030237](https://doi.org/10.3390/v11030237)

15. Tipih T, Heise M, Burt FJ. Immunogenicity of a DNA-Based Sindbis Replicon Expressing Crimean-Congo Hemorrhagic Fever Virus Nucleoprotein. *Vaccines (Basel)*. 2021;9:1491. [PubMed https://doi.org/10.3390/vaccines9121491](https://doi.org/10.3390/vaccines9121491)
16. Aligholipour Farzani T, Hanifehnezhad A, Földes K, Ergünay K, Yilmaz E, Hashim Mohamed Ali H, et al. Co-delivery effect of CD24 on the immunogenicity and lethal challenge protection of a DNA vector expressing nucleocapsid protein of Crimean Congo hemorrhagic fever virus. *Viruses*. 2019;11:75. [PubMed https://doi.org/10.3390/v11010075](https://doi.org/10.3390/v11010075)
17. Hawman DW, Ahlén G, Appelberg KS, Meade-White K, Hanley PW, Scott D, et al. A DNA-based vaccine protects against Crimean-Congo haemorrhagic fever virus disease in a cynomolgus macaque model. *Nat Microbiol*. 2020;6:187–95. [PubMed https://doi.org/10.1038/s41564-020-00815-6](https://doi.org/10.1038/s41564-020-00815-6)
18. Hinkula J, Devignot S, Åkerström S, Karlberg H, Watrang E, Bereczky S, et al. Immunization with DNA plasmids coding for Crimean-Congo hemorrhagic fever virus capsid and envelope proteins and/or virus-like particles induces protection and survival in challenged mice. *J Virol*. 2017;91:e02076-16. [PubMed https://doi.org/10.1128/JVI.02076-16](https://doi.org/10.1128/JVI.02076-16)
19. Scholte FEM, Spengler JR, Welch SR, Harmon JR, Coleman-McCray JD, Freitas BT, et al. Single-dose replicon particle vaccine provides complete protection against Crimean-Congo hemorrhagic fever virus in mice. *Emerg Microbes Infect*. 2019;8:575–8. [PubMed https://doi.org/10.1080/22221751.2019.1601030](https://doi.org/10.1080/22221751.2019.1601030)
20. Spengler JR, Welch SR, Scholte FEM, Coleman-McCray JD, Harmon JR, Nichol ST, et al. Heterologous protection against Crimean-Congo hemorrhagic fever in mice after a single dose of replicon particle vaccine. *Antiviral Res*. 2019;170:104573. [PubMed https://doi.org/10.1016/j.antiviral.2019.104573](https://doi.org/10.1016/j.antiviral.2019.104573)
21. Spengler JR, Welch SR, Scholte FEM, Rodriguez SE, Harmon JR, Coleman-McCray JD, et al. Viral replicon particles protect IFNAR^{-/-} mice against lethal Crimean-Congo hemorrhagic fever virus challenge three days after vaccination. *Antiviral Res*. 2021;191:105090. [PubMed https://doi.org/10.1016/j.antiviral.2021.105090](https://doi.org/10.1016/j.antiviral.2021.105090)
22. Berber E, Çanakoğlu N, Tonbak Ş, Ozdarendeli A. Development of a protective inactivated vaccine against Crimean-Congo hemorrhagic fever infection. *Heliyon*. 2021;7:e08161. [PubMed https://doi.org/10.1016/j.heliyon.2021.e08161](https://doi.org/10.1016/j.heliyon.2021.e08161)

23. Canakoglu N, Berber E, Tonbak S, Ertek M, Sozdutmaz I, Aktas M, et al. Immunization of knock-out α/β interferon receptor mice against high lethal dose of Crimean-Congo hemorrhagic fever virus with a cell culture based vaccine. PLoS Negl Trop Dis. 2015;9:e0003579. [PubMed](#)
<https://doi.org/10.1371/journal.pntd.0003579>
24. Pavel STI, Yetiskin H, Kalkan A, Ozdarendeli A. Evaluation of the cell culture based and the mouse brain derived inactivated vaccines against Crimean-Congo hemorrhagic fever virus in transiently immune-suppressed (IS) mouse model. PLoS Negl Trop Dis. 2020;14:e0008834. [PubMed](#)
<https://doi.org/10.1371/journal.pntd.0008834>

Article DOI: <https://doi.org/10.3201/eid3005.231648>

EID cannot ensure accessibility for supplementary materials supplied by authors. Readers who have difficulty accessing supplementary content should contact the authors for assistance.

Crimean-Congo Hemorrhagic Fever Virus for Clinicians—Diagnosis, Clinical Management, and Therapeutics

Appendix 2

Additional References

51. Watts DM, Ussery MA, Nash D, Peters CJ. Inhibition of Crimean-Congo hemorrhagic fever viral infectivity yields in vitro by ribavirin. *Am J Trop Med Hyg.* 1989;41:581–5. [PubMed](#)
<https://doi.org/10.4269/ajtmh.1989.41.581>
52. Paragas J, Whitehouse CA, Endy TP, Bray M. A simple assay for determining antiviral activity against Crimean-Congo hemorrhagic fever virus. *Antiviral Res.* 2004;62:21–5. [PubMed](#)
<https://doi.org/10.1016/j.antiviral.2003.11.006>
53. Celikbas AK, Dokuzoğuz B, Baykam N, Gok SE, Eroğlu MN, Midilli K, et al. Crimean-Congo hemorrhagic fever among health care workers, Turkey. *Emerg Infect Dis.* 2014;20:477–9. [PubMed](#)
<https://doi.org/10.3201/eid2003.131353>
54. Conger NG, Paolino KM, Osborn EC, Rusnak JM, Günther S, Pool J, et al. Health care response to CCHF in US soldier and nosocomial transmission to health care providers, Germany, 2009. *Emerg Infect Dis.* 2015;21:23–31. [PubMed](#)
<https://doi.org/10.3201/eid2101.141413>
55. Guven G, Talan L, Altintas ND, Memikoglu KO, Yoruk F, Azap A. An unexpected fatal CCHF case and management of exposed health care workers. *Int J Infect Dis.* 2017;55:118–21. [PubMed](#)
<https://doi.org/10.1016/j.ijid.2016.12.026>
56. Tütüncü EE, Gurbuz Y, Ozturk B, Kuscu F, Sencan I. Crimean Congo haemorrhagic fever, precautions and ribavirin prophylaxis: a case report. *Scand J Infect Dis.* 2009;41:378–80. [PubMed](#)
<https://doi.org/10.1080/00365540902882434>

57. Saleem J, Usman M, Nadeem A, Sethi SA, Salman M. Crimean-Congo hemorrhagic fever: a first case from Abbottabad, Pakistan. *Int J Infect Dis.* 2009;13:e121–3. [PubMed](#)
<https://doi.org/10.1016/j.ijid.2008.07.023>
58. Bangash SA, Khan EA. Treatment and prophylaxis with ribavirin for Crimean-Congo hemorrhagic fever—is it effective? *J Pak Med Assoc.* 2003;53:39–41. [PubMed](#)
59. Roberts SS. Assessing ribavirin exposure during pregnancy: the Ribavirin Pregnancy Registry. *Gastroenterol Nurs.* 2008;31:413–7. [PubMed](#) <https://doi.org/10.1097/SGA.0b013e31818eb70d>
60. Hawman DW, Haddock E, Meade-White K, Williamson B, Hanley PW, Rosenke K, et al. Favipiravir (T-705) but not ribavirin is effective against two distinct strains of Crimean-Congo hemorrhagic fever virus in mice. *Antiviral Res.* 2018;157:18–26. [PubMed](#)
<https://doi.org/10.1016/j.antiviral.2018.06.013>
61. Tignor GH, Hanham CA. Ribavirin efficacy in an in vivo model of Crimean-Congo hemorrhagic fever virus (CCHF) infection. *Antiviral Res.* 1993;22:309–25. [PubMed](#)
[https://doi.org/10.1016/0166-3542\(93\)90040-P](https://doi.org/10.1016/0166-3542(93)90040-P)
62. Bodur H, Erbay A, Akıncı E, Öngürü P, Bayazıt N, Eren SS, et al. Effect of oral ribavirin treatment on the viral load and disease progression in Crimean-Congo hemorrhagic fever. *Int J Infect Dis.* 2011;15:e44–7. [PubMed](#) <https://doi.org/10.1016/j.ijid.2010.09.009>
63. D’Addiego J, Elaldi N, Wand N, Osman K, Bagci BK, Kennedy E, et al. Investigating the effect of ribavirin treatment on genetic mutations in Crimean-Congo haemorrhagic fever virus (CCHFV) through next-generation sequencing. *J Med Virol.* 2023;95:e28548. [PubMed](#)
<https://doi.org/10.1002/jmv.28548>
64. Ascioğlu S, Leblebicioğlu H, Vahaboglu H, Chan KA. Ribavirin for patients with Crimean-Congo haemorrhagic fever: a systematic review and meta-analysis. *J Antimicrob Chemother.* 2011;66:1215–22. [PubMed](#) <https://doi.org/10.1093/jac/dkr136>
65. Arab-Bafrani Z, Jabbari A, Mostakhdem Hashemi M, Arabzadeh AM, Gilanipour A, Mousavi E. Identification of the crucial parameters regarding the efficacy of ribavirin therapy in Crimean-Congo haemorrhagic fever (CCHF) patients: a systematic review and meta-analysis. *J Antimicrob Chemother.* 2019;74:3432–9. [PubMed](#) <https://doi.org/10.1093/jac/dkz328>
66. Johnson S, Henschke N, Maayan N, Mills I, Buckley BS, Kakourou A, et al. Ribavirin for treating Crimean Congo haemorrhagic fever. *Cochrane Database Syst Rev.* 2018;6:CD012713. [PubMed](#)
<https://doi.org/10.1002/14651858.CD012713.pub2>

67. Soares-Weiser K, Thomas S, Thomson G, Garner P. Ribavirin for Crimean-Congo hemorrhagic fever: systematic review and meta-analysis. *BMC Infect Dis.* 2010;10:207. [PubMed](#)
<https://doi.org/10.1186/1471-2334-10-207>
68. Koksai I, Yilmaz G, Aksoy F, Aydin H, Yavuz I, Iskender S, et al. The efficacy of ribavirin in the treatment of Crimean-Congo hemorrhagic fever in eastern Black Sea region in Turkey. *J Clin Virol.* 2010;47:65–8. [PubMed](#) <https://doi.org/10.1016/j.jcv.2009.11.007>
69. Tchesnokov EP, Bailey-Elkin BA, Mark BL, Götte M. Independent inhibition of the polymerase and deubiquitinase activities of the Crimean-Congo hemorrhagic fever virus full-length L-protein. *PLoS Negl Trop Dis.* 2020;14:e0008283. [PubMed](#) <https://doi.org/10.1371/journal.pntd.0008283>
70. Oestereich L, Rieger T, Neumann M, Bernreuther C, Lehmann M, Krasemann S, et al. Evaluation of antiviral efficacy of ribavirin, arbidol, and T-705 (favipiravir) in a mouse model for Crimean-Congo hemorrhagic fever. *PLoS Negl Trop Dis.* 2014;8:e2804. [PubMed](#)
<https://doi.org/10.1371/journal.pntd.0002804>
71. Hawman DW, Haddock E, Meade-White K, Nardone G, Feldmann F, Hanley PW, et al. Efficacy of favipiravir (T-705) against Crimean-Congo hemorrhagic fever virus infection in cynomolgus macaques. *Antiviral Res.* 2020;181:104858. [PubMed](#)
<https://doi.org/10.1016/j.antiviral.2020.104858>
72. Dülger AC, Yakarişik M, Uzun YE, Şahin AM. Treatment of Crimean-Congo haemorrhagic fever by favipiravir in a patient with novel coronavirus co-infection. *Eur J Case Rep Intern Med.* 2020;7:002042. [PubMed](#)
73. Pilkington V, Pepperrell T, Hill A. A review of the safety of favipiravir—a potential treatment in the COVID-19 pandemic? *J Virus Erad.* 2020;6:45–51. [PubMed](#) [https://doi.org/10.1016/S2055-6640\(20\)30016-9](https://doi.org/10.1016/S2055-6640(20)30016-9)
74. Ohlstein EH, Vickery L, Sauermelch C, Willette RN. Vasodilation induced by endothelin: role of EDRF and prostanoids in rat hindquarters. *Am J Physiol.* 1990;259:H1835–41. [PubMed](#)
75. Ergonul O. Treatment of Crimean-Congo hemorrhagic fever. *Antiviral Res.* 2008;78:125–31. [PubMed](#)
<https://doi.org/10.1016/j.antiviral.2007.11.002>
76. Fillâtre P, Revest M, Tattevin P. Crimean-Congo hemorrhagic fever: an update. *Med Mal Infect.* 2019;49:574–85. [PubMed](#) <https://doi.org/10.1016/j.medmal.2019.09.005>
77. Mardani M, Rahnavardi M, Sharifi-Mood B. Current treatment of Crimean-Congo hemorrhagic fever in children. *Expert Rev Anti Infect Ther.* 2010;8:911–8. [PubMed](#) <https://doi.org/10.1586/eri.10.67>

78. Berber I, Korkmaz S, Sarici A, Erkurt MA, Kuku I, Kaya E, et al. Therapeutic plasma exchange for envenomation: Is it reasonable? *Transfus Apheresis Sci.* 2021;60:103241. [PubMed](#)
<https://doi.org/10.1016/j.transci.2021.103241>
79. Beştepe Dursun Z, Korkmaz S, Türe Z, Kaynar L, Dursun A, Çelik İ. Efficacy of therapeutic plasma exchange in patients with Crimean-Congo hemorrhagic fever. *J Clin Apher.* 2021;36:390–7. [PubMed](#) <https://doi.org/10.1002/jca.21875>
80. Meço BC, Memikoğlu O, İlhan O, Ayyıldız E, Gunt C, Unal N, et al. Double filtration plasmapheresis for a case of Crimean-Congo hemorrhagic fever. *Transfus Apheresis Sci.* 2013;48:331–4. [PubMed](#) <https://doi.org/10.1016/j.transci.2013.04.011>
81. Perk O, Emeksiz S, Ozcan S, Meral G. Crimean-Congo hemorrhagic fever: A pediatric case responding to plasmapheresis treatment. *Transfus Apheresis Sci.* 2021;60:103215. [PubMed](#)
<https://doi.org/10.1016/j.transci.2021.103215>
82. Oygur PD, Gürlevik SL, Sağ E, İlbay S, Aksu T, Demir OO, et al. Changing disease course of Crimean-Congo hemorrhagic fever in children, Turkey. *Emerg Infect Dis.* 2023;29:268–77. [PubMed](#) <https://doi.org/10.3201/eid2902.220976>
83. Dilber E, Cakir M, Erduran E, Koksall I, Bahat E, Mutlu M, et al. High-dose methylprednisolone in children with Crimean-Congo haemorrhagic fever. *Trop Doct.* 2010;40:27–30. [PubMed](#)
<https://doi.org/10.1258/td.2009.090069>
84. Sharifi-Mood B, Alavi-Naini R, Metanat M, Mohammadi M, Shakeri A, Amjadi A. Efficacy of high-dose methylprednisolone in patients with Crimean-Congo haemorrhagic fever and severe thrombocytopenia. *Trop Doct.* 2013;43:49–53. [PubMed](#)
<https://doi.org/10.1177/0049475513486642>
85. Dokuzoguz B, Celikbas AK, Gök ŞE, Baykam N, Eroglu MN, Ergönül Ö. Severity scoring index for Crimean-Congo hemorrhagic fever and the impact of ribavirin and corticosteroids on fatality. *Clin Infect Dis.* 2013;57:1270–4. [PubMed](#) <https://doi.org/10.1093/cid/cit527>
86. Vassilenko SM, Vassilev TL, Bozadjiev LG, Bineva IL, Kazarov GZ. Specific intravenous immunoglobulin for Crimean-Congo haemorrhagic fever. *Lancet.* 1990;335:791–2. [PubMed](#)
[https://doi.org/10.1016/0140-6736\(90\)90906-L](https://doi.org/10.1016/0140-6736(90)90906-L)
87. van Eeden PJ, van Eeden SF, Joubert JR, King JB, van de Wal BW, Michell WL. A nosocomial outbreak of Crimean-Congo haemorrhagic fever at Tygerberg Hospital. Part II. Management of patients. *S Afr Med J.* 1985;68:718–21. [PubMed](#)

88. Kubar A, Haciomeroglu M, Ozkul A, Bagriacik U, Akinci E, Sener K, et al. Prompt administration of Crimean-Congo hemorrhagic fever (CCHF) virus hyperimmunoglobulin in patients diagnosed with CCHF and viral load monitorization by reverse transcriptase-PCR. *Jpn J Infect Dis.* 2011;64:439–43. [PubMed https://doi.org/10.7883/yoken.64.439](https://doi.org/10.7883/yoken.64.439)
89. Golden JW, Shoemaker CJ, Lindquist ME, Zeng X, Daye SP, Williams JA, et al. GP38-targeting monoclonal antibodies protect adult mice against lethal Crimean-Congo hemorrhagic fever virus infection. *Sci Adv.* 2019;5:eaaw9535. [PubMed https://doi.org/10.1126/sciadv.aaw9535](https://doi.org/10.1126/sciadv.aaw9535)
90. Fels JM, Maurer DP, Herbert AS, Wirchnianski AS, Vergnolle O, Cross RW, et al. Protective neutralizing antibodies from human survivors of Crimean-Congo hemorrhagic fever. *Cell.* 2021;184:3486–3501.e21. [PubMed https://doi.org/10.1016/j.cell.2021.05.001](https://doi.org/10.1016/j.cell.2021.05.001)